TrialCardiovascular diabetology2022

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.

Charlotte C van Ruiten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.